SURMOUNT-5 was a 72-week, open-label, Phase 3b randomised trial of 751 adults with obesity but without diabetes, comparing maximum-tolerated tirzepatide (10 or 15 mg) against maximum-tolerated semaglutide (1.7 or 2.4 mg)
While some people report faster absorption in the abdomen, the difference is unlikely to have a significant impact on the overall effectiveness of the medication
While semaglutide provides substantial metabolic benefits, its GI AEs, most notably nausea, vomiting, diarrhoea, and constipation, can compromise treatment adherence, particularly during the early dose-escalation phase
Some researchers also use a peptide reconstitution calculator to double-check their math before adding water
Nov 17, 2025: Updated Shed pricing throughout the article, including brand-name and compounded medication ranges